First To Reach 3rd Phase Clinical Trial In Korea
In cooperation with the leading university on traditional Korean medicine, we have *developed safe and natural drugs that help with memory loss, enhance coordination and concentration, combat depression, dementia and Alzheimer’s. Unlike the current drugs on the market offered for fighting dementia that come with a long list of severe side-effects, *our products not only combat the condition itself, but works in synergy with your body to provide you better overall health. Seeing as to how the progression of Alzheimer’s will become the single greatest economic burden on societies around the world, we strive to make a great impact to keep that at bay.
For more information, visit our website at www.mediforum.co
To purchase Mediforum products, please visit www.mediforum.us
For viewers outside of the United States:
*This statement has been evaluated by the Ministry of Food and Drug Safety in Korea.
For viewers in the United States:
*This statement has not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Overview
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 25, 2022 | Mediforum becomes first Korean pharmaceutical company to be scheduled to list on NASDAQ | Mediforum MOU Signing Ceremony in Seoul, Korea Mediforum MOU Signing Ceremony Streamed Live Mediforum to explore Phase III clinical trial of PM-012 with the US Food and Drug Administration for the treatment of dementia and Alzheimer’s disea... |
Reviews 0
FAQ about Mediforum
What has the press written about Mediforum?
Parsers VC has collected 2 articles mentioning Mediforum, among them “Mediforum becomes first Korean pharmaceutical company to be scheduled to list on NASDAQ” (Nov 25, 2022).
Is Mediforum still active?
Yes, Mediforum is active; its latest activity on Parsers VC dates from Jan 22, 2024.